Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First Evaluation of GenoType MTBDRplus 2.0 Performed Directly on Respiratory Specimens in Central America.

Journal of clinical microbiology - 1 Oct 2016

Lanzas Fedora, Ioerger Thomas R, Shah Harita, Acosta William, Karakousis Petros C

Abstract excerpt

The turnaround times for conventional methods used to detect Mycobacterium tuberculosis in sputum samples and to obtain drug susceptibility information are long in many developing countries, including Panama, leading to delays in appropriate treatment initiation and continued transmission in the community. We evaluated the performance of a molecular line probe assay, the Genotype MTBDRplus version 2.0 assay, in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Catalase
Share to DNA-Directed RNA Polymerases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Diagnostic Techniques

Share to Nitrate Reductase

Share to Oxidoreductases

Share to Panama

Share to Sputum

Share to Tuberculosis, Pulmonary

Source

Open in PubMed Open full text

Identifiers

PMID: 27440816
DOI: 10.1128/JCM.01196-16
PMCID: PMC5035431

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First Evaluation of GenoType MTBDRplus 2.0 Performed Directly on Respiratory Specimens in Central America.PMID 27440816Read ↗

The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay.Semantic proximity Read ↗

Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay.Semantic proximity Read ↗

Diagnostic performance of genoType® MTBDRplus line probe assay in bronchoalveolar lavage for pulmonary tuberculosis diagnosis in sputum scarce and smear-negative patients.Semantic proximity Read ↗

First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances.Semantic proximity Read ↗

Multicenter Noninferiority Evaluation of Hain GenoType MTBDR <i>plus</i> Version 2 and Nipro NTM+MDRTB Line Probe Assays for Detection of Rifampin and Isoniazid ResistanceSemantic proximity Read ↗

Analytical performance of a multi-target open real-time PCR assay for simultaneous detection of tuberculosis, non-tuberculous mycobacteria, and drug resistance in a high-burden settingSemantic proximity Read ↗

Diagnostic performance of the GenoType MTBDRplus VER 2.0 line probe assay for the detection of isoniazid resistant Mycobacterium tuberculosis in Ethiopia.Semantic proximity Read ↗

Accuracy of genotype MTBDRplus line probe assay in patients with tuberculous pleural effusion: comparison with clinical and culture based diagnosis.Semantic proximity Read ↗

Evaluation of genotype MTBDRplus VER 2.0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples.Semantic proximity Read ↗

In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosisSemantic proximity Read ↗

The performance of Xpert MTB/RIF and MTBDRplus within a Programmatic setting at TB Laboratory in Rio de Janeiro, Brazil.Semantic proximity Read ↗

Genotype MTBDRsl version 2 and phenotypic drug resistance detection of Mycobacterium tuberculosis for fluoroquinolones and aminoglycosides.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.